Prevalence and Correlates of metabolic syndrome among people living with HIV receiving dolutegravir-based ART in Northwest Ethiopia: A cross-sectional study

Abstract

OBJECTIVES: Antiretroviral therapy (ART) has been associated with components of metabolic syndrome (MetS), including glucose intolerance, weight gain, and dyslipidemia. However, with the advent of newer agents such as dolutegravir (DTG), evidence on the burden of MetS remains limited. Therefore, this study aimed to assess the prevalence of MetS and its determinants among people living with HIV (PLWH) receiving DTG-based ART at Debre Markos Comprehensive Specialized Hospital (DMCSH), Northwest Ethiopia. METHODS: An institution-based cross-sectional study was conducted from December 1, 2021, to February 28, 2022, among 422 randomly selected participants using face-to-face interviews, anthropometric assessments, medical chart reviews, and biochemical measurements. MetS was defined based on the 2009 harmonized criteria. Epi-Data version 4.6 and SPSS version 26 were used for data entry and statistical analysis, respectively. Bivariable and multivariable logistic regression analyses were employed to identify factors associated with MetS. A statistical significance was decided at P ≤ 0.05. RESULTS: (AOR: 1.73; 95% CI: 1.1-2.73) were significantly associated with MetS. CONCLUSION: were significantly associated with MetS. Routine clinical monitoring and assessment of all MetS components are recommended for PLWH receiving DTG-based ART, with particular attention to those who consume alcohol, have inadequate physical activity, elevated BMI, or higher CD4+ T-cell count.